Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Phase 2 Completed NCT06482112

Condition	Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Phase	Phase 2
Sponsor	Merck Sharp & Dohme LLC
Status	Completed
Enrollment	124 participants
Interventions	Efinopegdutide
Start date	Jul 29, 2024
Completion date	Jun 27, 2025
Results posted	Jun 1, 2026

Summary

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.

Mean Relative Reduction From Baseline in Liver Fat Content at Week 28

Baseline and Week 28 · Percent Reduction

Efinopegdutide Q1W 10 mg	67.8 Percent Reduction
Efinopegdutide Q2W 10 mg	54.4 Percent Reduction
Efinopegdutide Q2W 15 mg	42.1 Percent Reduction

Percentage of Participants Who Experienced an Adverse Event (AE)

Up to Week 32 · Percentage of participants

Efinopegdutide Q1W 10 mg	83.3 Percentage of participants
Efinopegdutide Q2W 10 mg	82.1 Percentage of participants
Efinopegdutide Q2W 15 mg	85.7 Percentage of participants

Percentage of Participants Who Discontinued Study Intervention Due to an AE

Up to Week 28 · Percentage of participants

Efinopegdutide Q1W 10 mg	7.1 Percentage of participants
Efinopegdutide Q2W 10 mg	5.1 Percentage of participants
Efinopegdutide Q2W 15 mg	9.5 Percentage of participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский